Abstract
The aim of the management of chronic myeloid leukemia (CML) in the time of pregnancy is to treat efficiently the woman and simultaneously allow the successful fetal developInent and the delivery of a healthy individual. In the case the pregnancy is find out during the treatment with any tyrosine kinase inhibitor the treatment should be immediately stopped in order to avoid the risk of fetal exposure.
In the case of newly diagnosed CML in the time of pregnancy leukodepletion and from the second trimester also interferonal alfa represent the safe and effective therapy. After the achievement of long-term molecular response there is a possibility to plan the treatment interruption in order to allow conception with subsequent pregnancy.
Today, the pregnancy in patients with CML is possible however, in each case it is the pregnancy at risk both for the women and the child requiring the individual approach and the close cooperation of the hematologist with geneticist and gynecologist.